Skip to main content
Fig. 3 | BMC Health Services Research

Fig. 3

From: Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada

Fig. 3

DSA results for the ICERs of RZV versus no HZ vaccine for Canadian HSCT adultsa. All costs are in 2022 Canadian dollars. aOnly the top 10 results are shown. DSA, deterministic sensitivity analysis; HSCT, hematopoietic stem-cell transplant; HZ, herpes zoster; ICER, incremental cost-effectiveness ratio; PHN, postherpetic neuralgia; QALY, quality-adjusted life-year; RZV, recombinant zoster vaccine; YOA, years of age

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us